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Introduction
Down syndrome is the most commonly encountered
chromosomal abnormality in newborns, with an inci-
dence of 1 in 800 live births. In addition to decreased
mentality, about half of cases have associated congeni-
tal heart disease. Down syndrome, therefore, has a sub-
stantial socioeconomic impact. A first-trimester com-
bined test at 10 to 13 weeks’ gestation is effective in
detecting Down syndrome [1–9]. The test consists of
measurements of sonographic fetal nuchal translucency
(NT) thickness, and serum levels of pregnancy-associated
plasma protein-A (PAPP-A) and free β-human chorio-
nic gonadotropin (fβ-hCG). At a 5% false-positive rate,
this test can detect Down syndrome in an additional
15% to 20% of cases compared with second-trimester
biochemical screening [9–12].
SUMMARY
Objective: To assess the sensitivity of a first-trimester combined screening test for fetal chromosomal abnormalities.
Materials and Methods: From April 1999 to December 2002, 5,036 unselected women with singleton
pregnancies underwent a first-trimester combined test (nuchal translucency thickness, pregnancy-associated
plasma protein-A, and free β-human chorionic gonadotropin) screening for Down syndrome. They included
298 (5.9%) women aged 35 years or older and 4,738 (94.1%) women aged below 35 years. A positive result
was defined as an estimated Down syndrome risk of greater than 1/270.
Results: Twenty-five (0.50%) chromosomal abnormalities were identified, with a false-positive rate of 7.1%
(333/4,717) in women younger than 35 years and a false-positive rate of 17.3% (51/294) in women of advanced
maternal age. The 25 chromosomal abnormalities included trisomy 21 in six fetuses, trisomy 18 and Turner’s
syndrome in four fetuses each, Klinefelter’s syndrome, a marker chromosome and pseudohermaphroditism
in one fetus each, and structural rearrangements in eight, including four with balanced translocations. One
fetus with trisomy 18 was not discovered at screening, but a fetal ventricular septal defect was found on ultrasound
at 30 weeks’ gestation. The detection rate for fetal chromosomal abnormalities was 95.2% (20/21). If a cutoff
of 1 in 200 was used, the false-positive rate would be 5.6% with the same detection rate, whereas the test
still yielded a detection rate of 90.5% (19/21) with a 5% false-positive rate. In 83.3% of cases with trisomy
21 and 5.7% of normal pregnancies, fetal nuchal translucency thickness measurement was above the 95th
percentile, whereas in 0.7% of the study population and in 24% of those with fetal chromosomal abnormalities,
the fetal nuchal translucency thickness was at least 3 mm.
Conclusions: Our results indicate that the first-trimester combined test for Down syndrome is effective in
identifying fetal chromosomal abnormalities. Moreover, the measurement of fetal nuchal translucency thickness
at 10 to 13 weeks of gestation enables early detection of major fetal structural anomalies. [Taiwanese J Obstet
Gynecol 2004;43(2):72–76]
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The combined test for Down syndrome first-trimester
screening has been offered as an option to pregnant
women at Cathay General Hospital since April 1999.
This study analyzed the usefulness of the technique in
detecting fetal chromosomal abnormalities.
Materials and Methods
From April 1999 to December 2002, a total of 5,036 un-
selected women with singleton pregnancies elected to
have the combined test. The test involves measuring
sonographic fetal NT thickness and maternal serum
levels of fβ-hCG and PAPP-A at 10 to 13 weeks of ges-
tation. Fetal NT thickness was measured according to
the criteria of the Fetal Medicine Foundation in the UK
[13]. Maternal serum levels of fβ-hCG and PAPP-A were
determined within 1 week by microtiter-plate enzyme-
linked immunosorbent assay (ELISA) according to the
manufacturer’s protocol (Free β-hCG PNS EIA Kit and
PAPP-A EIA Kit, Genemed Biotechnologies, South San
Francisco, CA, USA). NT thickness, PAPP-A, and fβ-
hCG values were divided by their respective day-specific
medians to determine the multiples of the median
(MoM) for each marker. Down syndrome risk was cal-
culated using Alpha Software (Logical Medical Sys-
tems, London, UK) based on a multivariate Gaussian
distribution as described by Wald et al [14]. A positive
result was defined as an estimated Down syndrome risk
of more than 1/270.
All chromosome analyses were carried out in the
Cytogenetics Laboratory of Cathay General Hospital.
For cultured chorionic villus tissue and amniocytes, four
primary cultures were performed using an in situ method
with CHANG MEDIUM® BMC (Irvine Scientific, Santa
Ana, CA, USA). Microscopic analysis of Giemsa-stained
chromosome banding used the rules for metaphase
selection and colony definition as defined by Moertel et
al [15].
Results
Among the 5,036 women, 298 (5.9%) were aged 35
years or older, and 4,738 (94.1%) were aged below 35
years. The median maternal age was 30.0 years, median
maternal weight was 53.5 kg, and median gestational
age at screening was 83 days. Table 1 shows the me-
dian values of NT thickness, PAPP-A, and fβ-hCG at
10 to 13 weeks of gestation. The median NT thickness
was 1.0 mm, median PAPP-A was 3.5 mIU/mL, and
median fβ-hCG was 50.0 mIU/mL. There were 406
positive-screen pregnancies which occurred in 7.5%
(353/4,738) of women younger than 35 years and
17.8% (53/298) of women of advanced maternal age.
Fetal NT thickness was above the 95th percentile in
83.3% of cases with trisomy 21 and in 5.7% of normal
pregnancies, whereas it was at least 3 mm in 0.7% of
all pregnancies and in 24% of those with fetal chromo-
somal abnormalities.
Fetal karyotyping results were available for 309 (76%)
of the 406 positive screening results. The other women
were lost to follow-up, and no information regarding
the outcome of their pregnancies was available; all
pregnancies whose outcomes were unknown were as-
sumed to be normal. Seven women underwent chorio-
nic villus sampling in the first trimester, while the re-
maining 302 women underwent amniocentesis in the
second trimester. Twenty-five chromosomal abnor-
malities were identified, including trisomy 21 in six
fetuses, trisomy 18 in four, Turner’s syndrome in four,
Klinefelter’s syndrome in one, a marker chromosome in
one, pseudohermaphroditism in one, and structural re-
arrangements in eight, including four with balanced
translocations. One fetus with trisomy 18 was not dis-
covered at screening, but a ventricular septal defect was
found by ultrasonography at 30 weeks’ gestation.
Detailed screening results for the 25 cases with
chromosomal abnormalities are shown in Table 2. A
combination of a low PAPP-A level, a high fβ-hCG level,
and increased NT thickness was noted in cases of tri-
somy 21 and monosomy X, whereas low levels of both
PAPP-A and fβ-hCG were observed in cases of trisomy
18. Table 3 shows the detection and false-positive rates
for fetal chromosomal abnormalities at different cutoff
points. The same detection rate of 95.2% was achieved
when the false-positive rate was lowered from 7.1% to
5.6%, which suggests that it would be reasonable to
change the risk cutoff from the present 1 in 270 to 1 in
200. At a fixed 5% false-positive rate, the detection rate
of the combined test in other studies ranged from 80%
to 91% (Table 4) [1,3–5,7,9]. Table 5 illustrates the
screening performance of the combined test for fetal
Table 1. Median levels of screening markers at
10–13 weeks of gestation
 GA NT PAPP-A fβ-hCG
(wk) (mm) (mIU/mL) (mIU/mL)
 10 0.8 2.1 65.0
 11 0.9 2.9 53.0
 12 1.0 4.2 46.0
 13 1.0 5.4 37.0
GA = gestational age; NT = nuchal translucency thickness; PAPP-A =
pregnancy-associated plasma protein-A; fβ-hCG = free beta-human chorionic
gonadotropin.
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Table 2. Screening data for the 25 cases with fetal chromosomal abnormalities
MA GA NT fβ-hCG PAPP-A DR Fetal karyotype
(yr)  (d)  (MoM)  (MoM)  (MoM)
 37 81 1.37 1.49 0.6 1/240 46,XY,female
 25 80 5.23* 1.08 0.53 1/3 45,X
 37 93 2.02 0.59 0.2 1/16 47,XY,+18
 31 89 2.2 2.67 0.37 1/16 47,XX,+21
 22 90 0.71 3.13 0.13 1/90 45,X/47,XXX
 31 84 0.55 0.25 0.48 1/29,000 47,XY,+18
 32 90 8.86* 0.9 0.92 1/2 47,XX,+marker
 26 80 9.78* 2.27 0.44 1/2 45,X
 30 79 2.01 1.68 0.2 1/3 46,XY[21]/45,X[4]
 30 86 2.14 1.55 0.23 1/4 47,XY,+21
 34 76 14.2* 2.4 1 1/2 47,XY,+18
 30 79 2.92 1.92 1.35 1/4 46,XY,t(6;16)(q14;q22)
 34 72 2 1.22 1.21 1/150 46,XY,t(14;17)(q31;q24)pat
 33 75 2.06 0.69 0.67 1/65 45,XX,der(13;14)(q10;q10)mat
 33 82 3.14 1.11 0.63 1/2 47,XY,+21
 32 84 1.76 0.61 0.43 1/120 47,XX,+21
 30 97 1.28 4.77 0.48 1/85 45,XX,der(15;22)(q10;q10)
 36 88 1.14 1.18 1.3 1/2,000 47,XXY
 29 82 2.07 3.45 1.07 1/20 46,XX,ins(11;7)(p15.1;q31.1q21.2)
 31 85 7.03* 0.19 0.39 1/2 47,XX,+18
 30 86 2.91 2.88 0.89 1/2 47,XX,+21
 29 82 1.96 1.44 0.39 1/18 46,X,del(X)(q23;q25)
 29 84 2.81 0.66 1.02 1/9 46,XY,del(18)(p11.1)
 32 80 2.05 1.97 0.3 1/3 47,XY,+21
 36 82 1.17 0.62 0.68 1/1,700 46,XX,del(X)(p22.2;p21.2)
MA = maternal age; GA = gestational age by ultrasound dating at the time of screening; NT = nuchal translucency thickness; fβ-hCG = free beta-human
chorionic gonadotropin; PAPP-A = pregnancy-associated plasma protein-A; MoM = multiples of median; DR = Down syndrome risk. *NT ≥ 3 mm.
Table 3. Observed detection rates and false-positive rates for fetal chromosomal abnormalities using different
risk cutoffs
Risk cutoff, %
1/140 (n = 237) 1/200 (n = 286) 1/270 (n = 353)
DR FP DR FP DR FP
Total 190.5 5.0 `95.2 5.6 195.2 7.1
T21 100.0 5.0 100.0 5.6 100.0 7.1
T18 175.0 5.0 175.0 5.6 175.0 7.1
45,X 100.0 5.0 100.0 5.6 100.0 7.1
n = number of positive screens in women aged below 35 years; DR = detection rate; FP = false-positive rate; T21 = trisomy 21; T18 = trisomy 18.
chromosomal abnormalities. The overall detection rate
was 88.0%, with a false-positive rate of 7.7%.
Discussion
In this study, we demonstrated that in women younger
than 35 years, the detection rate of fetal chromosomal
abnormalities using the first-trimester combined test
was 95.2% (at a risk cutoff of 1:270), with a false-
positive rate of 7.1%. Even with a fixed 5% false-positive
rate, the test still yielded a detection rate of 90.7% (at a
risk cutoff of 1:140). As shown in Table 4, these results
are in accordance with previous studies, which reported
a detection rate in the range of 80% to 91% with a 5%
false-positive rate. In addition to its higher detection
rate, the combined test has also been shown to be more
sophisticated and cost-effective than other second-
trimester screening protocols [16–18]. However, in Tai-
wan, second-trimester maternal serum screening based
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on the combination of maternal age, α-fetoprotein,
and fβ-hCG remains the most widely used Down syn-
drome screening protocol. This yields a detection rate
of only 56% to 70% for a false-positive rate of 5%
[9–12,19]. Therefore, we encourage tertiary centers
in Taiwan to implement the combined test as part of
the clinical Down syndrome screening protocol.
The effectiveness of the combined test heavily
depends on the accuracy of the sonographic measure-
ment of fetal NT thickness. Standardization and quality
control of fetal ultrasound NT examinations should
therefore be emphasized [7]. Accurate measurement
of NT thickness should be undertaken by fully quali-
fied, well-trained sonographers who strictly follow the
guidelines of the Fetal Medicine Foundation [13]. In
this study, we found that in 83.3% of trisomy 21 cases
and 5.7% of normal pregnancies, the fetal NT thickness
measured was above the 95th percentile of the normal
range. These results are similar to the rates of 73.7% and
4.8%, respectively, reported by von Kaisenberg et al [8].
Thus, ultrasonographic measurement of first-trimester
NT thickness is feasible and useful in identifying Down
syndrome. This screening method also identified 24%
(6/25) of the fetal chromosomal abnormalities based
on the finding of an NT thickness of at least 3 mm.
However, fetal NT thickness alone is not an efficient
screening marker for Down syndrome in the first tri-
mester, because in order to achieve a detection rate of
85%, the false-positive rate would be as high as 21.1%.
When combined with PAPP-A and fβ-hCG, the false-
positive rate was only 6% with the same detection rate
of 85% [12].
Deviations from the medians of the screening markers
have been associated with adverse pregnancy outcomes
[20–23]. Increased NT thickness is not only associated
with congenital heart defects, chromosomal abnor-
malities, and fetal loss, but also with gestational hyper-
tension and pre-eclampsia [22]. Low serum PAPP-A in
the first trimester is also associated with fetal growth
retardation, gestational hypertension, preterm deliv-
ery, and spontaneous miscarriage [23]. Therefore, in
addition to detecting fetal aneuploidies, the combined
test can identify women at increased risk of adverse
pregnancy outcomes.
Recent reports have indicated that the integrated
test will probably be the test of choice for high-
Table 5. Screening performance of the combined test for fetal chromosomal abnormalities
Overall Women < 35 yr Women ≥ 35 yr
A B A B A B
Screen positive, n 22 1384 20 1333 2 151
Screen negative, n 13 4,627 11 4,384 2 243
Total 25 5,011 21 4,717 4 294
Detection rate, % 88.0  95.2 50.0
Specificity, % 92.3  92.9 82.7
Positive predictive value, % 15.4 1 5.7 13.8
Negative predictive value, % 99.9 100.0 99.2
Prevalence, % 10.5 110.4 11.3
False-positive rate, % 17.7 117.1 17.3
Screen-positive rate, % 18.1 117.5 17.8
A = number of affected cases; B = number of unaffected cases.
Table 4. Comparison of published studies giving detection and false-positive rates for trisomy 21 using the
first-trimester combined test at various risk cutoffs
Authors n Markers DR (%) FP (%) Risk cutoff
Spencer et al (1999) [1] 210 NT + fβ-hCG + PAPP-A 189.0 5.0 1/270
Wald et al (1999) [3] 177 NT + fβ-hCG + PAPP-A 185.0 5.0 1/250
Krantz et al (2000) [4] 150 NT + fβ-hCG + PAPP-A 191.0 5.0 1/270
Bindra et al (2002) [5] 182 NT + fβ-hCG + PAPP-A 190.2 5.0 1/215
Crossley et al (2002) [7] 181 NT + fβ-hCG + PAPP-A 182.0 5.0 1/250
Wald & Hackshaw (1997) [9] 163 NT + fβ-hCG + PAPP-A 180.0 5.0 1/390
Current study 6 NT + fβ-hCG + PAPP-A 100.0 5.0 1/140
All protocols include maternal age. n = number of cases; NT = nuchal translucency thickness; fβ-hCG = free beta-human chorionic gonadotropin; PAPP-
A = pregnancy-associated plasma protein-A; DR = detection rate; FP = false-positive rate.
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performance Down syndrome screening. The Serum,
Urine and Ultrasound Screening Study showed that the
integrated test, which includes NT thickness and five
serum markers, yielded an 85% detection rate at a false-
positive rate of 1.2%, and a 93% detection rate at a false-
positive rate of 4.5% [12].
In women of advanced maternal age, the current
standard of care is to offer an invasive prenatal diagnosis
with amniocentesis or chorionic villus sampling. In this
study, the detection rate in women of advanced maternal
age was only 50% at a false-positive rate of 17.3%. We
would not recommend the first-trimester combined test
for women of advanced age; instead, the integrated test
might be a better option. However, further study is
required to address this issue so that the number of
amniocentesis- and unnecessary procedure-related fetal
losses can be reduced.
In conclusion, this study demonstrates that the
combined test is an effective Down syndrome screening
protocol in the first trimester. Furthermore, the sono-
graphic measurement of fetal NT thickness at 10 to 13
weeks of gestation is a useful tool for the early diag-
nosis of fetal structural anomalies.
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